JP2021503892A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503892A5
JP2021503892A5 JP2020528052A JP2020528052A JP2021503892A5 JP 2021503892 A5 JP2021503892 A5 JP 2021503892A5 JP 2020528052 A JP2020528052 A JP 2020528052A JP 2020528052 A JP2020528052 A JP 2020528052A JP 2021503892 A5 JP2021503892 A5 JP 2021503892A5
Authority
JP
Japan
Prior art keywords
cancer
tbm
tumor
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020528052A
Other languages
English (en)
Japanese (ja)
Other versions
JP7542438B2 (ja
JPWO2019104075A5 (enExample
JP2021503892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/062078 external-priority patent/WO2019104075A1/en
Publication of JP2021503892A publication Critical patent/JP2021503892A/ja
Publication of JP2021503892A5 publication Critical patent/JP2021503892A5/ja
Publication of JPWO2019104075A5 publication Critical patent/JPWO2019104075A5/ja
Priority to JP2024138929A priority Critical patent/JP2024161539A/ja
Application granted granted Critical
Publication of JP7542438B2 publication Critical patent/JP7542438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020528052A 2017-11-21 2018-11-20 腫瘍関連抗原に対する三重特異性結合分子及びその使用 Active JP7542438B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024138929A JP2024161539A (ja) 2017-11-21 2024-08-20 腫瘍関連抗原に対する三重特異性結合分子及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589331P 2017-11-21 2017-11-21
US62/589,331 2017-11-21
PCT/US2018/062078 WO2019104075A1 (en) 2017-11-21 2018-11-20 Trispecific binding molecules against tumor-associated antigens and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024138929A Division JP2024161539A (ja) 2017-11-21 2024-08-20 腫瘍関連抗原に対する三重特異性結合分子及びその使用

Publications (4)

Publication Number Publication Date
JP2021503892A JP2021503892A (ja) 2021-02-15
JP2021503892A5 true JP2021503892A5 (enExample) 2022-01-04
JPWO2019104075A5 JPWO2019104075A5 (enExample) 2023-02-02
JP7542438B2 JP7542438B2 (ja) 2024-08-30

Family

ID=66632159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020528052A Active JP7542438B2 (ja) 2017-11-21 2018-11-20 腫瘍関連抗原に対する三重特異性結合分子及びその使用
JP2024138929A Pending JP2024161539A (ja) 2017-11-21 2024-08-20 腫瘍関連抗原に対する三重特異性結合分子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024138929A Pending JP2024161539A (ja) 2017-11-21 2024-08-20 腫瘍関連抗原に対する三重特異性結合分子及びその使用

Country Status (10)

Country Link
US (1) US20200362054A1 (enExample)
EP (1) EP3713962A4 (enExample)
JP (2) JP7542438B2 (enExample)
KR (1) KR20200088440A (enExample)
CN (1) CN111601824B (enExample)
AU (2) AU2018370853A1 (enExample)
CA (1) CA3082283A1 (enExample)
IL (1) IL274591A (enExample)
RU (1) RU2020120411A (enExample)
WO (1) WO2019104075A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
JP7489407B2 (ja) * 2019-05-21 2024-05-23 ノバルティス アーゲー Cd19結合分子及びその使用
CA3253631A1 (en) 2019-05-31 2025-10-30 Zymeworks Bc Inc. Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of biliary tract cancers
WO2021195513A1 (en) * 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
CN113527497B (zh) * 2020-04-16 2022-06-10 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US12240899B2 (en) 2020-06-22 2025-03-04 Ngm Biopharmaceuticals, Inc. LAIR-1-binding agents and methods of use thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2022042576A1 (zh) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
US20240025993A1 (en) * 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
KR20230104256A (ko) * 2020-11-06 2023-07-07 암젠 인크 증가된 선택성의 다중표적화 이중특이적 항원 결합 분자
AU2021374083A1 (en) * 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
MX2023012974A (es) * 2021-05-04 2023-11-15 Regeneron Pharma Agonistas multiespecificos de receptores del fgf21 y sus usos.
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业(上海)股份有限公司 三特异性抗体、其制备方法和用途
WO2023006809A1 (en) * 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2
US20250332258A1 (en) * 2021-12-07 2025-10-30 The Scripps Research Institute Switchable car-t therapies for treating human cancers
TW202342549A (zh) * 2022-03-01 2023-11-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合flt3和cd3的抗原結合分子及其醫藥用途
WO2023199235A1 (en) * 2022-04-14 2023-10-19 Novartis Ag Dosage regimens for anti-cd19 agents and uses thereof
CN120035449A (zh) * 2022-10-08 2025-05-23 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
CN118420712A (zh) * 2023-02-01 2024-08-02 上海健信生物医药科技有限公司 一种三特异性抗体技术平台及其应用
TW202434644A (zh) * 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024240064A1 (zh) * 2023-05-19 2024-11-28 贝达药业股份有限公司 靶向抗原表位多肽的抗体药物偶联物及其应用
WO2024249387A2 (en) * 2023-05-29 2024-12-05 The Regents Of The University Of California T cell redirecting bispecific antibodies against cytomegaloviruses
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025080730A1 (en) * 2023-10-09 2025-04-17 Northwestern University Tri-specific t cell engager for treatment of glioblastoma
WO2025162207A1 (zh) * 2024-01-31 2025-08-07 上海复宏汉霖生物技术股份有限公司 抗liv1抗体及使用方法
WO2025209593A1 (zh) * 2024-04-06 2025-10-09 华深智药生物科技(苏州)有限公司 一种多特异性抗体t细胞衔接器

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
CN1822857A (zh) * 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
EP3770174A1 (en) * 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
ES2939760T3 (es) * 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
SG10201913324PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
SG11201701565PA (en) * 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
EP3237449A2 (en) * 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
CN107223135B (zh) * 2015-03-16 2021-11-02 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) 用于治疗hbv感染和相关病症的三特异性结合分子
EP3331913A1 (en) * 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
WO2017142928A1 (en) * 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021503892A5 (enExample)
RU2020120411A (ru) Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения
JPWO2019104075A5 (enExample)
JP2018527008A5 (enExample)
JP7438958B2 (ja) 新規な抗体分子、その調製方法及びその使用
JP2021502104A5 (enExample)
JP2022093564A5 (enExample)
JP2024045111A (ja) ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2019500394A5 (enExample)
JP2019534246A5 (enExample)
RU2018127657A (ru) Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
JP2020525032A5 (enExample)
JP2015527070A5 (enExample)
JP2017500869A5 (enExample)
JP2020513828A5 (enExample)
JP2017513818A5 (enExample)
CN110891650A (zh) 制导和导航控制蛋白及其制造和使用方法
JPWO2020052692A5 (enExample)
JP2018503399A5 (enExample)
JP2018507188A5 (enExample)
JP2022524906A (ja) 細胞免疫療法の組み合わせ
CN110072892A (zh) Mg7,高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US20240016841A1 (en) Cells comprising t cell-antigen couplers and uses thereof
KR20210145179A (ko) 스위치 가능한 키메라 항원 수용체-조작된 인간 자연 살해 세포
WO2022095801A1 (zh) 靶向lir1的抗体及其用途